Amyloid accumulation and tau-induced neurofibrillary changes are associated with the development of dementia (Bloom, 2014), and cerebrospinal fluid biomarkers such as amyloid-β42 and phosphorylated tau are known to be useful in the early diagnosis of Alzheimer’s disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.